Introduction {#s1}
============

Low bone mineral density (BMD) is common in patients with end-stage renal disease and chronic kidney disease (CKD), and hemodialysis (HD) increases the risk for bone loss and fractures. Low BMD is associated with the occurrence of new fractures, reduced quality of life, and increased mortality ([@B1], [@B2]). Thus, it is important to manage mineral and bone disorders (MBD) associated with CKD (CKD-MBD) ([@B3]). Additionally, HD patients commonly have decreased skeletal muscle mass and decreased muscle strength, known as sarcopenia ([@B4]). Both osteoporosis and sarcopenia are reportedly associated with poor mortality ([@B4], [@B5]). However, few studies have evaluated the association between BMD and skeletal muscle mass. Furthermore, some reports have shown that muscle mass is positively associated with BMD ([@B6], [@B7]), while other studies have not found this positive association ([@B8]). Therefore, the relationship between BMD and muscle mass in HD patients remains unclear. The present study examined the association between skeletal muscle mass index (SMI) and BMD in the lumbar spine and femoral neck in HD patients.

Materials and Methods {#s2}
=====================

The present study included patients with end-stage renal disease treated with intermittent HD who were older than 20 years. Patients with implanted pacemakers were excluded, as the presence of pacemaker prevents body fluid composition measurement using bioelectrical impedance analysis (BIA).

Fifty HD patients were recruited (31 men, 19 women; mean age, 69 ± 10 years; mean HD duration, 9.0 ± 8.8 years). The patients\' characteristics are summarized in [Table 1](#T1){ref-type="table"}. The causes of chronic renal failure were diabetes mellitus (17 patients), chronic glomerulonephritis (19 patients), nephrosclerosis (3 patients), and other (11 patients). Each patient underwent maintenance HD three times per week for 3--5 h in each session. Informed consent for study inclusion was obtained from each patient. The study was approved by the Institutional Review Board of Minami-Uonuma City Hospital (H29-12), Japan, and conformed to the provisions of the Declaration of Helsinki (revised in Tokyo in 2004).

###### 

Patient characteristics.

  **Characteristics**                         ***n* = 50**
  ------------------------------------------- --------------
  Sex male, *n* (%)                           31 (64)
  Age (years)                                 69 ± 10
  HD duration (year)                          9.0 ± 8.8
  **Primary disease**, ***n*** **(%)**        
      Diabetes mellitus                       17 (34)
      Nephrosclerosis                         3 (6)
      Chronic glomerulonephritis              19 (38)
      Others                                  11 (22)
  **Past medical history**, ***n*** **(%)**   
      Hypertension                            44 (88)
      Diabetes mellitus                       20 (40)
      Bone fracture                           9 (18)
      Ischemic heart disease                  8 (16)
  **Medication**, ***n*** **(%)**             
      Vitamin D                               34 (68)
      *P* binder                              42 (84)
      Calcimimetics                           11 (22)
  Body mass index (kg/m^2^)                   22.1 ± 4.6
  Systolic BP (mmHg)                          150 ± 23
  Diastolic BP (mmHg)                         78 ± 12
  Heart rate (/min)                           69 ± 12
  **Laboratory findings**                     
  Albumin (g/dL)                              3.5 ± 0.4
  Serum sodium (mEq/L)                        138 ± 3
  Serum potassium (mEq/L)                     4.9 ± 0.7
  Serum calcium, mg/dL                        8.4 ± 0.6
  Serum phosphate (mg/dL)                     5.1 ± 1.1
  BUN (mg/dL)                                 60 ± 13
  Cr (mg/dL)                                  10.1 ± 1.1
  Hb (g/dL)                                   11.2 ± 0.9
  Total cholesterol (mg/dL)                   156 ± 41
  Triglyceride (mg/dL)                        109 ± 68
  C-reactive protein (mg/dL)                  0.5 ± 0.9
  Intact PTH (pg/mL)                          154 ± 109
  ALP (U/L)                                   245 ± 101
  BAP (μg/mL)                                 16 ± 13
  TRACP-5b (mU/dL)                            491 ± 240
  ucOC (ng/mL)                                31 ± 15
  Total P1NP (ng/mL)                          257 ± 154
  **Physical status and BMD**                 
  Grip strength (kg)                          23 ± 8
  Skeletal muscle mass index (kg/m^2^)        6.1 ± 1.2
  Lumbar spine bone density (g/cm^2^)         0.91 ± 0.21
  Proxymal femur bone density (g/cm^2^)       0.56 ± 0.12

*HD, hemodialysis; BP, blood pressure; BUN, blood urea nitrogen; Cr, creatinine; Hb, hemoglobin; PTH, parathyroid hormone; ALP, alkaline phosphatase; BAP, bone specific alkaline phosphatase; TRACP-5b, tartrate-resistant acid phosphatase 5b; ucOC, undercarboxylated osteocalcin; P1NP, N-terminal propeptide of type I procollagen; BMD, bone mineral density*.

Data Collection
---------------

Baseline patient characteristics and other relevant data, including the primary disease of CKD, were collected from the medical records. Blood pressure and pulse rate were measured with patients in the supine position before the HD session at which each SMI measurement was taken. Body mass index (BMI) was calculated using the dry weight (DW). Blood samples were obtained from the arteriovenous fistula before HD.

Measurement of SMI, BMD, and Grip Strength
------------------------------------------

SMI was calculated using body composition measurements obtained with multi-frequency BIA (InBody S10; InBody Japan, Tokyo, Japan). A skeletal muscle mass evaluation was performed after the last HD session; that is, patients were measured under DW so that the weight was not affected by the amount of body fluid. Then, the SMI was calculated by normalizing the skeletal muscle mass for height (kg/m^2^).

Dual energy X-ray absorptiometry (Horizon A, HOLOGIC Japan, Tokyo, Japan) was used to evaluate the BMD in the lumbar spine (L2--L4) and femoral neck. To minimize variations in BMD measurements, a single radiologic technologist performed scanning and BMD data calculations for all HD patients.

Grip strength was measured by a grip strength meter (Smedley\'s Hand Dynamo Meter, Matsumiya Ika Seiki, Tokyo, Japan). Grip strength was measured twice for the hand without a dialysis shunt before the HD session. The mean of the two measurements was used as the grip strength for each patient.

Statistics
----------

Data are expressed as mean ± standard deviation. The paired Student\'s *t*-test was used to compare two parameters. Inter-group correlations were evaluated by Pearson\'s correlation coefficient and linear regression analysis. Multivariate linear regression analysis was performed using the parameters with statistically significant correlations in univariate analyses (*p* \< 0.05) to determine the independent factors that influenced the lumbar spine BMD and femoral neck BMD. All analyses were performed using SPSS Statistics version 19.0 (IBM, Armonk, NY, USA). Differences with a *p* \< 0.05 were considered statistically significant.

Results {#s3}
=======

The clinical parameters of the study participants are shown in [Table 1](#T1){ref-type="table"}. The lumbar spine BMD in all included HD patients was 0.91 ± 0.21 g/cm^2^. The lumbar spine BMD was significantly greater in men (0.96 ± 0.21 g/cm^2^) than in women (0.80 ± 0.20 g/cm^2^, *p* \< 0.01). The female neck BMD in all included HD patients was 0.56 ± 0.12 g/cm^2^. The femoral neck BMD was significantly greater in men (0.60 ± 0.12 g/cm^2^) than in women (0.49 ± 0.07 g/ cm^2^, *p* \< 0.01). In addition, the lumbar spine BMD was significantly greater than the femoral neck BMD (*p* \< 0.001). The SMI in all patients was 6.10 ± 1.20 kg/m^2^, and the grip strength was 23 ± 8 kg.

[Table 2](#T2){ref-type="table"} shows the correlations between each BMD and the clinical parameters. Simple linear regression analysis showed that the factors that significantly affected the lumbar spine BMD were sex, presence of hypertension, presence of diabetes mellitus, BMI, triglyceride level, grip strength, and SMI; the factors that significantly affected the femoral neck BMD were sex, HD duration, serum creatinine level, tartrate-resistant acid phosphatase 5b level, undercarboxylated osteocalcin (ucOC) level, total N-terminal propeptide of type I procollagen level, grip strength, and SMI. [Figure 1](#F1){ref-type="fig"} shows that SMI was positively correlated with both the lumbar spine BMD (*r* = 0.578, *p* \< 0.001) and the femoral neck BMD (*r* = 0.560, *p* \< 0.001). Additionally, the lumbar spine BMD was positively correlated with femoral neck BMD (*r* = 0.586, *p* \< 0.001; [Figure 1C](#F1){ref-type="fig"}).

###### 

Correlations between clinical parameters and respective BMD.

                                              **Lumbar spine**   **Femoral neck**            
  ------------------------------------------- ------------------ ------------------ -------- ---------
  Sex male, *n* (%)                           0.356              0.011              0.416    0.003
  Age (years)                                 −0.266             0.062              −0.275   0.053
  HD duration (year)                          −0.231             0.106              −0.311   0.027
  **Past medical history**, ***n*** **(%)**                                                  
      Hypertension                            0.283              0.046              0.178    0.216
      Diabetes mellitus                       0.330              0.019              0.178    0.216
      Bone fracture                           −0.227             0.112              −0.258   0.078
      Ischemic heart disease                  −0.147             0.308              −0.005   0.970
  Body mass index (kg/m^2^)                   0.435              0.002              0.270    0.058
  Systolic BP (mmHg)                          0.051              0.725              −0.078   0.591
  Diastolic BP (mmHg)                         −0.178             0.217              −0.195   0.175
  Heart rate (/min)                           −0.105             0.486              −0.172   0.232
  Albumin (g/dL)                              0.037              0.800              0.046    0.750
  Serum sodium (mEq/L)                        −0.065             0.652              −0.261   0.167
  Serum potassium (mEq/L)                     −0.199             0.166              0.018    0.899
  Serum calcium (mg/dL)                       0.111              0.443              0.061    0.675
  Serum phosphate (mg/dL)                     0.054              0.707              0.107    0.461
  BUN (mg/dL)                                 −0.052             0.718              0.072    0.620
  Cr (mg/dL)                                  0.227              0.113              0.301    0.034
  Hb (g/dL)                                   −0.011             0.939              −0.036   0.802
  Total cholesterol (mg/dL)                   0.096              0.508              0.111    0.443
  Triglyceride (mg/dL)                        0.298              0.035              0.278    0.051
  C-reactive protein (mg/dL)                  0.036              0.801              −0.005   0.972
  intact PTH (pg/mL)                          −0.017             0.905              −0.182   0.205
  ALP (U/L)                                   −0.075             0.606              −0.209   0.146
  BAP (μg/mL)                                 −0.210             0.143              −0.233   0.103
  TRACP-5b (mU/dL)                            −0.199             0.180              −0.419   0.002
  ucOC (ng/mL)                                −0.175             0.223              −0.382   0.006
  total P1NP (ng/mL)                          −0.145             0.314              −0.380   0.006
  Grip strength (kg)                          0.471              0.001              0.507    \<0.001
  Skeletal muscle mass index (kg/m^2^)        0.578              \<0.001            0.560    \<0.001

*HD, hemodialysis; BP, blood pressure; BUN, blood urea nitrogen; Cr, creatinine; Hb, hemoglobin; PTH, parathyroid hormone; ALP, alkaline phosphatase; BAP, bone specific alkaline phosphatase; TRACP-5b, tartrate-resistant acid phosphatase 5b; ucOC, undercarboxylated osteocalcin; P1NP, N-terminal propeptide of type I procollagen; BMD, bone mineral density*.

![**(A)** Correlation between SMI and the BMD of the lumbar spine. **(B)** Correlation between SMI and the BMD of the femoral neck. **(C)** Correlation between the BMD of the lumbar spine and the BMD of the femoral neck. SMI, skeletal muscle mass index; BMD, bone mineral density.](fmed-07-00187-g0001){#F1}

In multivariate analysis, the only factor that significantly affected the lumbar spine BMD was the SMI (standardized coefficient: 0.578), while the femoral neck BMD was significantly affected by the SMI (standardized coefficient: 0.468), ucOC level (standardized coefficient: −0.366), and sex (standardized coefficient: 0.231; [Table 3](#T3){ref-type="table"}).

###### 

Multivariate regression analysis: Independent factors of BMD in the lumbar spine and femoral neck.

  **BMD**        **Variables**   **Coefficient**   **Standardized coefficient**   ***p*-value**
  -------------- --------------- ----------------- ------------------------------ ---------------
  Lumbar spine   SMI             0.101             0.578                          \<0.001
  Femoral neck   SMI             0.046             0.468                          \<0.001
                 ucOC            −0.003            −0.366                         0.001
                 Sex (male:1)    0.055             0.231                          0.046

*BMD, bone mineral density; SMI, skeletal muscle mass index; ucOC, undercarboxylated osteocalcin*.

Discussion {#s4}
==========

The present study investigated the association between SMI and the BMD of the lumbar spine and the femoral neck. It is well-known that the risk of bone fracture is increased in dialysis patients ([@B1], [@B9]), and malnutrition and sarcopenia are associated with poor prognosis ([@B10], [@B11]). However, reports regarding the association between osteoporosis and sarcopenia in HD patients are limited ([@B6], [@B7], [@B12]). Similarly to these previous reports, our results demonstrated a positive correlation between SMI and BMD. Muscle, especially skeletal muscle, supports the bones and positively supports physical activity ([@B13]). Therefore, it is important to understand osteosarcopenia in HD patients with both CKD-MBD and malnutrition.

Osteosarcopenia is a new concept that includes both osteoporosis and sarcopenia, and leads to an increased risk of frailty ([@B14]). The incidence of osteosarcopenia in general population is reportedly 5.8% ([@B15]) and this incidence is likely to be even higher in HD patients. The prevalence of osteosarcopenia in patients with CKD who have undergone kidney transplantation is reportedly 17.2%, and these patients have a slower walking speed than patients without osteosarcopenia ([@B16]). In contrast, exercise contributes to BMD preservation ([@B17]), and exercise training improves grip strength and walking speed in dialysis patients ([@B18]). Therefore, the presence of osteosarcopenia, which decreases the ability to exercise, might be associated with negative cycles involving bone, skeletal muscle, and physical activity. In the clinical setting, HD patients must be properly managed, including the management of CKD-MBD to prevent both osteoporosis and sarcopenia.

In the present study, there were no correlation found between BMD and the levels of serum calcium, serum phosphate, and intact parathyroid hormone. Furthermore, BMD was not associated with bone turnover or osteogenesis markers. However, various therapeutic agents were used to appropriately manage the CKD-MBD status of patients undergoing HD and the CKD-MBD related data was well controlled. This might be the reason that these makers were not found to be significant independent factors associated with BMD in the present study. In contrast, previous studies have found that some bone turnover or osteogenesis markers were independently associated with BMD ([@B6], [@B7]). These markers were also associated with the femoral neck BMD in simple liner regression performed in the present study. However, although bone metabolism-related makers were not associated with BMD, SMI was independently associated with BMD. A previous study reported that the femoral neck BMD was affected by body weight and serum creatinine level, which could reflect muscle mass ([@B19]). Therefore, the maintenance of skeletal muscle might be important in preventing BMD. Further prospective studies are required to clarify the association between CKD-MBD or bone metabolism and BMD.

In the present study, the femoral neck BMD was significantly affected by the ucOC level. Osteocalcin is one of the factors related to bone formation, and is induced by vitamin K. In patients with vitamin K deficiency, osteocalcin is mainly present in the circulation as ucOC, which is reportedly inversely correlated with vitamin K ([@B20]). Furthermore, an increased ucOC level is a risk factor for hip fracture ([@B21]), and vitamin K levels are also associated with bone fracture in HD patients ([@B22]). Therefore, improving vitamin K deficiency could be important for the transformation of osteocalcin. However, HD patients should pay attention to their diet, even if they are vitamin K deficient, as foods such as vegetables, tea, and seaweed that contain vitamin K have high levels of potassium. Although vitamin K and ucOC are not routinely measured in dialysis clinics, these might be useful measurements for maintaining BMD or preventing bone fracture.

Although grip strength had a strong correlation with BMD in simple linear regression in the present study, it was not found to be an independent factor affecting the BMD of the lumbar spine or femoral neck because grip strength is reportedly a good predictor of overall muscle strength and a useful marker of frailty ([@B23]). Furthermore, the distal radius BMD is reportedly one of the determinants of handgrip strength ([@B7]). If the present study has evaluated the muscle strength in the lumbar spine or femur, muscle strength might have been found to be an independent factor affecting the BMD. Therefore, the association between muscle strength and BMD should be investigated in future studies.

The present study has some limitations. First, the sample size was relatively small. Second, this study was a cross-sectional study, and therefore, causal relationships cannot be confirmed. Third, as HD patients are at increased risk of bone fracture or mortality due to the influences of CKD-MBD, various medications used to treat CKD-MBD were prescribed throughout HD therapy. Therefore, a prospective longitudinal study is needed to investigate the associations between BMD and changes in CKD-MBD factors.

In conclusion, SMI was independently associated with the BMD of lumbar spine and femoral neck. Therefore, to prevent BMD decrease in HD patients, it may be important to preserve skeletal muscle mass in addition to performing CKD-MBD management.
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